Efficacy of lomefloxacin as compared to norfloxacin in the treatment of uncomplicated urinary tract infections in adults

https://doi.org/10.1016/0002-9343(92)90314-2Get rights and content

Abstract

The efficacy and safety of 7–10-day courses of lomefloxacin (single daily dose of 400 mg) or norfloxacin (twice-daily doses of 400 mg) for the treatment of uncomplicated urinary tract infections were compared in two large, multicenter, randomized trials. This article presents the combined results of these trials, which were conducted in a total of 27 centers throughout the United States. A total of 727 adults, mostly women, with symptoms of acute urinary tract infection were enrolled; 370 patients were randomized to lomefloxacin treatment, and 357 received norfloxacin. The bacteriologic cure rate at 5–9 days post-therapy was 98.2% in the lomefloxacin group and 96.3% in the norfloxacin group (p = nonsignificant). The clinical success rate of 99.1% in the lomefloxacin group was significantly higher than the success rate of 93.5% in the norfloxacin group (p = 0.002). Adverse events were reported by 157 lomefloxacin-treated patients and 129 patients receiving norfloxacin. Adverse events attributable to drug treatment occurred in 41 patients (11.1%) in the lomefloxacin group and 27 (7.6%) in the norfloxacin group. Eight lomefloxacin (2.2%) and three norfloxacin patients (0.8%) were withdrawn from treatment because of adverse events probably attributable to the drug. The incidence of dizziness, tremor, and photosensitivity rash was higher in the lomefloxacin group than in the norfloxacin group, while the incidence of nausea was higher in the norfloxacin group. The results of these trials demonstrate that once-daily administration of 400 mg lomefloxacin is as safe and effective clinically as, and superior bacteriologically to, twice-daily administration of 400 mg norfloxacin in the treatment of acute uncomplicated urinary tract infections in adult patients.

References (27)

  • R Wise et al.

    In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents

    Antimicrob Agents Chemother

    (1988)
  • T Hirose et al.

    In vitro and in vivo activity of NY-198, a new difluorinated quinolone

    Antimicrob Agents Chemother

    (1987)
  • N-X Chin et al.

    In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones

    Antimicrob Agents Chemother

    (1988)
  • AM Clarke et al.

    Comparative in vitro activity of lomefloxacin, a new difluoroquinolone

    Eur J Clin Microbiol Infect Dis

    (1989)
  • PJ Morrison et al.

    Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses

    Antimicrob Agents Chemother

    (1988)
  • JJ Schentag et al.

    Pharmacokinetics and tissue penetration of the quinolones

  • PR Edwards et al.
  • FD Schoenknecht et al.
  • ACO Bauer et al.

    Antibiotic susceptibility testing by a standardized single dose method

    Am J Clin Pathol

    (1966)
  • SAS Institute

    SAS user's guide: statistics

  • J Fleiss

    Statistical methods for rates and proportions

  • EJ Goldstein et al.

    Ciprofloxacin versus cinoxacin in therapy of urinary tract infections

    Am J Med

    (1987)
  • Cited by (20)

    • Photosensitivity induced by lomefloxacin versus other fluoroquinolones: A meta-analysis

      2020, Journal of Infection and Chemotherapy
      Citation Excerpt :

      All analyses were conducted using Comprehensive Meta-Analysis Version 3 software (Biostat, Englewood, NJ, USA). The search process identified 392 articles; a total of four RCTs (with a total of 2295 patients) were included [22–25] after screening by title and/or abstract and then by full-text (Fig. 1). The characteristics of the included studies are summarized in Table 2 and the quality assessment of these studies is provided in Table 3.

    • Photochemical decomposition of Lomefloxacin in vitro and in vivo

      2000, Journal of Photochemistry and Photobiology B: Biology
    • Urinary tract infections

      1992, The American Journal of Medicine
    • Infection in the elderly: Studies with lomefloxacin

      1992, The American Journal of Medicine
    View all citing articles on Scopus
    View full text